Our mission

From healthcare data to decision-ready evidence,helping treatments reach patients earlier

Our mission is to make clinical development a continuous learning process—so each study builds on existing knowledge and brings effective treatments closer to patients.

Evinexus builds digital twin cohorts from real-world oncology data, so sponsors can plan trials that need fewer patients and reach decisions earlier.

Discuss your next study See the validation evidence

Most trials relearn what earlier studies already showed.

Each randomized trial enrolls its own control arm, even when earlier trials and routine care have already shown how patients on the standard of care fare. That adds enrollment and follow-up time, asks more patients to take the comparator, and keeps rigorous trials out of reach for many smaller sponsors and rarer cancers.

We believe what one study learns should strengthen the next.

What changes when each study builds on existing knowledge

  1. Smaller control arms

    Digital twin cohorts can supplement or stand in for a trial's control arm, so more enrolled patients receive the treatment under study.

  2. Earlier decisions

    Existing control evidence can bring a trial's primary analysis forward, and feasibility and design questions can be tested before the first patient enrolls.

  3. Trials within reach of more sponsors

    Smaller trials let smaller sponsors pursue rigorous development, including in cancers too rare to fill a large control arm.

  4. Evidence that holds up to review

    Each cohort is reviewed by clinicians and tested by reproducing completed randomized trials, without exposing any individual's records.

See how digital twins reproduced completed trials

Plan trials that need fewer patients, with digital twin data and a platform built to support them

License a cohort for a defined study question and use the evidence platform to examine its characteristics, outcomes and assumptions. Scientific support connects the data to the analysis.

Contact us

Digital Twin Data

Patient-level oncology cohorts built around your indication, eligibility criteria, endpoints and follow-up, delivered ready to answer your study questions

Rare and orphan oncology focusLongitudinal endpointsDelivered in a standardized format ready for analysis
See the digital twin data product

Evidence Platform

A workspace for examining cohort characteristics, comparing outcomes, and reviewing scenario assumptions to inform your study design

Cohort explorationOutcome comparisonScenario assumptions
See the evidence platform

Evinexus scientists support feasibility, study design, analysis, and interpretation.

Earlier answers at every stage of development

External control arms

Earlier patients provide an external control for a single-arm trial.

Explore external control arms

Hybrid control arms

Digital twin controls supplement the randomized control arm so it can be smaller.

Explore hybrid control arms

Subgroup targeting

Digital twin cohorts show where the effect concentrates, by biomarker, line of therapy or regimen, so eligibility can be sharpened.

Explore subgroup targeting

Platform and adaptive trials

Several arms share one control as they enter and leave, with digital twin controls augmenting the randomized one.

Explore platform and adaptive trials
Explore all applications

Digital twin emulation of CheckMate-057 resulted in 194 days earlier readout

Retrospective study · Overall survival · advanced non-squamous NSCLC

Results are retrospective and study-specific. Prospective and regulatory validation remains required.

See how CheckMate-057 was reproduced

Room to test more promising treatments

When each trial builds on what is already known, the same patients and time can test more treatments, including in patient populations that conventional trial designs leave behind.

Discuss your next study